CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aura Biosciences, a clinical-stage biopharmaceutical company developing a novel class of tumor targeted therapies for initial application in primary tumors such as choroidal melanoma, today announced the dosing of the…
Author: Business Wire
Nouvelles données sur Enspryng (Satralizumab) de Chugai sur le risque et la sévérité des rechutes dans le trouble du spectre de la neuromyélite optique (NMOSD)
TOKYO–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKYO : 4519) a annoncé la présentation de nouvelles données sur Enspryng® (nom générique : satralizumab [recombinaison génétique]) dans la réduction de la sévérité des rechutes dans le traitemen…
中外製藥的Enspryng (Satralizumab)影響泛視神經脊髓炎(NMOSD)復發風險和嚴重程度的新資料
東京–(BUSINESS WIRE)–(美國商業資訊)—中外製藥株式會社(TOKYO:4519)發表Enspryng®（學名：satralizumab [基因重組])降低中樞神經系統罕見疾病泛視神經脊髓炎(NMOSD)復發嚴重程度的新資料。上述資料於第8屆ACTRIMS-ECTRIMS聯合會議MS Virtual 2020上呈報，同時呈報有關Enspryng降低NMOSD復發風險持久效應的長期有效性和安全性資料及其效益風險特性。Enspryng是中外製藥研製的一種pH依賴性結合型人類化抗IL-6…
Samenvatting: Nieuwe gegevens van Chugai’s Enspryng (Satralizumab) over risico en ernst van terugval bij neuromyelitis optica spectrum disorder (NMOSD)
TOKIO–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) kondigde de presentatie aan van nieuwe Enspryng® (generieke naam: satralizumab [genetische recombinatie]) gegevens over het verminderen van de ernst van terugval bij de behandeling v…
Resumen: Nuevos datos de Enspryng (satralizumab) de Chugai sobre el riesgo y la gravedad de la recaída en el trastorno del espectro óptico de la neuromielitis (NMOSD)
TOKIO–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKIO:4519) ha anunciado la presentación de nuevos datos de Enspryng® (nombre genérico: satralizumab [recombinación genética]) sobre la reducción de la gravedad de las recaídas en el tratamiento …
Desk Lamps With Seoul Semiconductor’s SunLike Series Natural Spectrum LEDs Sold at Costco, to Support Children’s Learning and Protection From Myopia
ANSAN, South Korea–(BUSINESS WIRE)– #BetterSleep–Desk lamps with Seoul Semiconductor SunLike Series natural spectrum LEDs, which help improve learning and protect from myopia, sales at Costco.
Neue Daten von Chugais Enspryng (Satralizumab) zu Risiko und Schweregrad eines Rückfalls bei Neuromyelitis-optica-Spektrum-Erkrankungen (NMOSD)
TOKIO–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) kündigten die Präsentation neuer Enspryng®-Daten (generischer Name: Satralizumab [genetische Rekombination]) zur Verringerung der Schwere des Rückfalls bei der Behandlung von Neuromy…
Optikos Receives ISO 13485:2016 Medical Device Certification
WAKEFIELD, Mass.–(BUSINESS WIRE)– #contractmanufacturing–Optikos Corporation receives ISO 13485:2016 certification for the design, manufacture, and distribution of medical devices.
Kala Pharmaceuticals to Host Key Opinion Leader Symposium on Unmet Need in Dry Eye Disease and Potential for EYSUVIS™
WATERTOWN, Mass.–(BUSINESS WIRE)–Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will host a ke…
Ashvattha Therapeutics to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
REDWOOD CITY, Calif.–(BUSINESS WIRE)–Ashvattha Therapeutics, a biotech company focused on developing novel hydroxyl dendrimer therapeutics (HDTs) to treat unmet medical needs in oncology, ocular, and inflammatory diseases, today announced that Jeffre…
Immunomic Therapeutics Inc. Expands into South Korea
SEOUL–(BUSINESS WIRE)–Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, originating in the United States recently opened its first office in Sout…
Lineage Cell Therapeutics to Present at H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020 and at Cantor Virtual Global Healthcare Conference on September 17, 2020
CARLSBAD, Calif.–(BUSINESS WIRE)—- $LCTX #AMD–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that Brian M. Culley, Chie…
Ocular Therapeutix™ Announces First Patient Dosed in Phase 3 Clinical Trial of DEXTENZA® for the Treatment of Post-Surgical Ocular Inflammation and Pain in Children
BEDFORD, Mass.–(BUSINESS WIRE)—- $OCUL #OCUTX–Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today…
Riassunto: In arrivo i nuovi dati riguardanti Enspryng (satralizumab) di Chugai sul rischio e la gravità delle recidive nel disturbo dello spettro della neuromielite ottica (NMOSD)
TOKYO–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) ha annunciato la presentazione di nuovi dati su Enspryng® (nome generico: satralizumab [ricombinazione genetica]) riguardo alla riduzione della gravità delle recidive nel trattamento …
New Data of Chugai’s Enspryng (Satralizumab) on Risk and Severity of Relapse in Neuromyelitis Optica Spectrum Disorder (NMOSD)
TOKYO–(BUSINESS WIRE)– #NMOSD–Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced the presentation of new Enspryng® (generic name: satralizumab [genetical recombination]) data on reducing relapse severity in the treatment of neuromyelitis optica …
New Data Show Genentech’s Enspryng Significantly Reduces Severity and Risk of Relapse in Neuromyelitis Optica Spectrum Disorder
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), will present new Enspryng™ (satralizumab-mwge) data on reducing relapse severity in the treatment of neuromyelitis optica spectrum disord…
IpVenture Offers Eyewear Technology for COVID-19
SAN JOSE, Calif.–(BUSINESS WIRE)– #covid–IpVenture offers patented technologies for COVID-19 eyewear to selected partners at a nominal fee.
Lineage Cell Therapeutics and AgeX Therapeutics Announce Expansion of Agreement Related to ESI Clinical-Grade Pluripotent Stem Cell Lines for Therapeutic Purposes
CARLSBAD, Calif. & ALAMEDA, Calif.–(BUSINESS WIRE)—- $LCTX #AMD–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, ES Cell International Pt…
New Preclinical Study Finds Niagen® Prevents Light-Induced Retinal Damage in Mice
LOS ANGELES–(BUSINESS WIRE)—- $CDXC #CellularHealth–ChromaDex Corp. (NASDAQ:CDXC) today announced new preclinical research published in Investigative Ophthalmology & Visual Science finding Niagen® (patented nicotinamide riboside, or NR) prevent…
NextGen Healthcare, Inc. to Present at Upcoming Investor Conferences
IRVINE, Calif.–(BUSINESS WIRE)—- $NXGN #AmbulatoryHealthcare–NextGen Healthcare announced that President and CEO, Rusty Frantz and CFO, Jamie Arnold, will participate in upcoming investor conferences.